ストックスクリーナーアプリを入手
88.33
1.31%
-1.17
アフターアワーズ：
88.33
Apogee Therapeutics Inc (APGE) 最新ニュース
Apogee Therapeutics CEO Michael Henderson sells $1.67m in stock - Investing.com
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics shareholders elect directors and approve proposals at annual meeting - Investing.com India
Apogee Therapeutics (APGE) CEO sells 20,000 shares in planned trades, keeps over 1.09M - Stock Titan
Apogee Therapeutics (NASDAQ: APGE) investors back board, pay and auditor - Stock Titan
Apogee Therapeutics (APGE) links 7,657-share option grant to director - Stock Titan
Apogee Therapeutics (APGE) director receives stock options for 7,657 shares - Stock Titan
Apogee Therapeutics (APGE) director Lisa Bollinger granted 7,657 stock options - Stock Titan
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Shah Nimish P - Moomoo
Goldman Sachs Maintains Apogee Therapeutics(APGE.US) With Hold Rating, Maintains Target Price $89 - Moomoo
APGE Stock Price, Quote & Chart - ChartMill
Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding - Yahoo Finance
These 10 mid-cap US healthcare companies carry the market's most expensive valuations - MSN
TD Asset Management Inc Has $9.76 Million Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Behavioral Patterns of APGE and Institutional Flows - Stock Traders Daily
APGE Maintained by RBC Capital -- Price Target Raised to $97.00 - GuruFocus
RBC Capital raises Apogee Therapeutics stock price target to $97 By Investing.com - Investing.com Australia
RBC Raises Price Target on Apogee Therapeutics to $97 From $82, Keeps Sector Perform, Speculative Risk - marketscreener.com
RBC Capital raises Apogee Therapeutics stock price target to $97 - Investing.com
Apogee Therapeutics CMO Dambkowski sells $432,904 in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO Dambkowski sells $432,904 in stock - Investing.com
Apogee Therapeutics (APGE) CMO trades stock under Rule 10b5-1 plan - Stock Titan
Blackstone pledges $1.3 billion to help develop Apogee skin drug - MSN
Apogee (APGE) Secures Up to $1.3B in Non-Dilutive Financing from Blackstone to Advance Zumilokibart - Insider Monkey
Should Positive Phase 2 Zumilokibart Data and Blackstone Funding Reshape the Outlook for Apogee Therapeutics (APGE) Investors? - Sahm
Apogee Therapeutics readies Zumi for phase 3 with Blackstone backing - MSN
Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing - sharewise.com
APGE: Strong phase II-B results and a $1.3B Blackstone deal drive late-stage and combo program expansion - TradingView
Deutsche Bank Adjusts PT on Apogee Therapeutics to $116 From $118, Maintains Buy Rating - marketscreener.com
Apogee Therapeutics (APGE) Among Most Expensive U.S. Healthcare Stocks by Valuation - GuruFocus
These 10 mid-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 2 APEX Results For Zumilokibart - Yahoo Finance
Apogee Therapeutics shares surge following $1.3 billion Blackstone financing partnership (APOG) - MSN
Latham & Watkins Advises Apogee Therapeutics in US$1.3 Billion Strategic Financing Collaboration With Blackstone Life Sciences, One of the Largest Life Sciences Financings of 2026 - Legal Desire
Apogee falls following Phase 2 results for zumilokibart in atopic dermatitis - MSN
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic DermatitisSlideshow (NASDAQ:APGE) 2026-05-30 - Seeking Alpha
A Quick Look at Today's Ratings for Apogee Therapeutics(APGE.US), With a Forecast Between $81 to $131 - Moomoo
Analysts Offer Insights on Healthcare Companies: Agilent (A), Apogee Therapeutics (APGE) and Pfizer (PFE) - The Globe and Mail
(APGE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Apogee Stock in Focus After Blackstone Announces $1.3 Billion Deal - Bez Kabli
Apogee Therapeutics to Participate in Upcoming June Conferences - The Manila Times
Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing (APGE) - Seeking Alpha
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program - Yahoo Finance
1.04%
0.76%
大文字化:
|
ボリューム (24 時間):